Subject(s)
Bacteremia/diagnosis , Bacteremia/microbiology , Immunocompromised Host , Lactococcus/isolation & purification , Liver Abscess/diagnosis , Liver Abscess/microbiology , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/microbiology , Streptococcal Infections/diagnosis , Streptococcal Infections/microbiology , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Biliary Tract Neoplasms/surgery , Cholangiocarcinoma/surgery , Diagnosis, Differential , Fatal Outcome , Female , Humans , Liver Abscess/drug therapy , Microbial Sensitivity Tests , Prosthesis-Related Infections/drug therapy , Streptococcal Infections/drug therapySubject(s)
Ascariasis/parasitology , Gastric Mucosa/parasitology , Animals , Ascariasis/therapy , Fishes/parasitology , Gastroscopy , Humans , Male , Middle AgedABSTRACT
Relapse rates were studied in one hundred patients in a multicentric, randomized trial during and after maintenance therapy comparing sucralfate, cimetidine and placebo. These patients were previously treated by cimetidine for peptic ulcer and were considered cured after endoscopic examination. Outpatients were randomly assigned to a 6 month maintenance treatment with either cimetidine (600 mg daily), sucralfate (300 mg daily) or a placebo. All patients underwent endoscopic evaluation after 3 and 6 months of therapy. A clinical évaluation was performed 6 months after all treatment had ceased. Clinical and endoscopic results proved the significant superiority of both sucralfate and cimetidine over the placebo. Remission rates with sucralfate were respectively 80,4 p. 100 after 6 months and 68,5 p. 100 after 12 months. These results were slightly superior to those observed with cimetidine (69,3 p. 100 and 61,3 p. 100). However, this difference is not statistically significant. Results for the placebo group were 47,9 p. 100 and 37,7 p. 100. Sucralfate is an effective medication in preventing the recurrence of peptic ulcer. Its pharmacological action, its few side effects and its effectiveness seem to make this medication very interesting in treating the ulcerous disease.
Subject(s)
Aluminum/therapeutic use , Cimetidine/therapeutic use , Duodenal Ulcer/drug therapy , Stomach Ulcer/drug therapy , Anti-Ulcer Agents/therapeutic use , Clinical Trials as Topic , Female , Humans , Male , Random Allocation , Recurrence , Sucralfate , Time FactorsABSTRACT
Cimetidine was studied in 8 cases of Zollinger-Ellison syndrome. The average dose was 1,2 g a day for 14 to 195 days. The treatment was remarkably effective in 2 cases, but only partial or temporary improvement was noted in 3 other cases. The last 3 patients failed to respond to treatment. The possibility of a rebound phenomenon requires strict clinical and biological supervision.
Subject(s)
Cimetidine/therapeutic use , Guanidines/therapeutic use , Histamine H2 Antagonists/therapeutic use , Zollinger-Ellison Syndrome/drug therapy , Administration, Oral/methods , Adult , Cimetidine/administration & dosage , Female , Humans , Male , Middle AgedABSTRACT
Five patients with Zollinger-Ellison syndrome received metiamide per os in doses ranging from 600 to 1,200 mg/day for a minimum period of 2 weeks. Drug produced an inhibition of basal gastric acid secretion ranging from 5 to 100% with relief of symptoms. Survey of patients during and after metiamide course showed sometimes a prolonged antisecretory effect up to 26 days after the end of treatment or, on the contrary, a reduced drug activity in spite of increasing doses.
